Citation only
via Europe PMC
Advanced Glycation End Products: From Pathogenesis to Treatment.
Lo TH, Zou J, Zhang J, Lin K, Zhu M, Lu S, Liu X, Wu M.
MedComm · 2026
Abstract
Advanced glycation end products (AGEs) are chemically heterogeneous modifications generated through nonenzymatic glycation, glycoxidation, and carbonyl stress. Their accumulation increases during aging and is accelerated by hyperglycemia, oxidative stress, inflammation, exogenous exposure, and impaired renal clearance. Although AGE biology has often been framed around the AGE-RAGE-oxidative stress axis, current evidence supports a broader systems-level model in which AGE burden reflects the balance among formation, detoxification, tissue retention, and clearance. This review summarizes AGE chemistry, endogenous and exogenous sources, detoxification pathways, receptor systems, and mechanisms of AGE-mediated tissue injury. We distinguish two complementary pathogenic routes: receptor-independent structural damage, including protein dysfunction, proteostatic stress, extracellular matrix crosslinking, and altered tissue mechanics; and receptor-dependent signaling, mainly through RAGE-mediated redox-inflammatory amplification. We then examine the clinical relevance of AGEs in diabetes, cardiovascular disease, chronic kidney disease, neurovascular and retinal dysfunction, fibrosis, and aging-related tissue decline. Particular attention is given to compartment-specific biomarker interpretation, because circulating free adducts, protein-bound AGEs, tissue autofluorescence, dietary AGE estimates, and dicarbonyl stress markers are not interchangeable. Finally, we evaluate therapeutic strategies and propose a framework that matches each intervention to the relevant mechanism and can be tested clinically. In doing so, the review clarifies major conceptual and methodological uncertainties in AGE research and provides a foundation for more rigorous biomarker interpretation, study design, and clinical translation.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1002/mco2.71073
- Canonical
- link ↗
- Fetched
- 2026-10-20 MST
Cite this
APA
TH, L., J, Z., J, Z., K, L., M, Z., S, L., X, L., & M., W. (2026). Advanced Glycation End Products: From Pathogenesis to Treatment. <em>MedComm</em>. https://doi.org/10.1002/mco2.71073
Vancouver
TH L, J Z, J Z, K L, M Z, S L, et al. Advanced Glycation End Products: From Pathogenesis to Treatment. MedComm. 2026. doi:10.1002/mco2.71073.
BibTeX
@article{lo2026Advanc,
title = {Advanced Glycation End Products: From Pathogenesis to Treatment.},
author = {Lo TH and Zou J and Zhang J and Lin K and Zhu M and Lu S and Liu X and Wu M.},
journal = {MedComm},
year = {2026},
doi = {10.1002/mco2.71073},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
International Journal of Molecular Sciences 2026
Open access · CC-BY
The AGE–RAGE–DIAPH1 Axis in Type 2 Diabetes and Metabolic Dysfunction: From Carbonyl Stress to Diabetic Myocardial and Neuronal Injury
World Journal of Diabetes 2014
Open access · CC-BY
Molecular mechanisms of AGE/RAGE-mediated fibrosis in the diabetic heart
Antioxidants 2025
Open access · CC-BY
Oxidative Stress, Advanced Glycation End Products (AGEs), and Neurodegeneration in Alzheimer’s Disease: A Metabolic Perspective
Biomedicines 2023
Open access · CC-BY
Oxidative Stress in Health and Disease
Redox Biology 2014
Open access · CC-BY
Role of advanced glycation end products in cellular signaling
Frontiers in Aging 2026
Open access · CC-BY